Suggest Mavenclad as a Second-Line Option for Multiple Sclerosis
March 2018
You'll start hearing about Mavenclad (MAY-ven-clad, cladribine), another oral option for relapsing-remitting multiple sclerosis.
Explain efficacy seems similar to other oral agents. Expect roughly 19 fewer relapses for every 100 patients on Mavenclad or Tecfidera (dimethyl fumarate) for one year...compared to 17 fewer with Aubagio (teriflunomide) or 22 fewer with Gilenya (fingolimod).
Continue to use interferon beta-1a (Avonex, Rebif), interferon beta-1b (Betaseron, Extavia), or glatiramer (Copaxone) first-line.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 200+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive